Charles Schwab Investment Management Inc. Boosts Stock Holdings in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT)

Charles Schwab Investment Management Inc. grew its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) by 1.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 197,622 shares of the biotechnology company’s stock after acquiring an additional 3,224 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.73% of Arcturus Therapeutics worth $4,587,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently bought and sold shares of the company. Sumitomo Mitsui Trust Holdings Inc. boosted its holdings in shares of Arcturus Therapeutics by 22.4% in the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 1,563,065 shares of the biotechnology company’s stock worth $38,061,000 after buying an additional 286,546 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. raised its stake in Arcturus Therapeutics by 45.6% in the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,275,715 shares of the biotechnology company’s stock valued at $52,819,000 after acquiring an additional 712,650 shares during the period. Empire Life Investments Inc. bought a new stake in Arcturus Therapeutics in the 3rd quarter valued at about $3,498,000. XTX Topco Ltd bought a new stake in shares of Arcturus Therapeutics during the second quarter valued at about $596,000. Finally, Squarepoint Ops LLC bought a new stake in shares of Arcturus Therapeutics during the second quarter valued at about $718,000. 94.54% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Arcturus Therapeutics news, COO Pad Chivukula sold 12,000 shares of the stock in a transaction on Tuesday, October 15th. The stock was sold at an average price of $20.76, for a total value of $249,120.00. Following the completion of the transaction, the chief operating officer now owns 435,334 shares in the company, valued at approximately $9,037,533.84. This represents a 2.68 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 15.30% of the stock is owned by corporate insiders.

Arcturus Therapeutics Stock Performance

NASDAQ:ARCT opened at $17.21 on Friday. The firm has a market cap of $466.22 million, a PE ratio of -7.75 and a beta of 2.62. Arcturus Therapeutics Holdings Inc. has a fifty-two week low of $14.93 and a fifty-two week high of $45.00. The business has a 50 day moving average price of $19.04 and a 200-day moving average price of $22.52.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.44. The company had revenue of $41.67 million during the quarter, compared to analyst estimates of $49.16 million. Arcturus Therapeutics had a negative return on equity of 22.39% and a negative net margin of 36.39%. During the same quarter last year, the firm posted ($0.61) earnings per share. Research analysts predict that Arcturus Therapeutics Holdings Inc. will post -2.31 EPS for the current year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the company. HC Wainwright reiterated a “buy” rating and set a $63.00 price target on shares of Arcturus Therapeutics in a research report on Friday, November 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Arcturus Therapeutics currently has an average rating of “Buy” and an average price target of $66.75.

Arcturus Therapeutics Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.